Cephalon Looks For Growth as Nuvigil Fails Schizophrenia Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
With sales leader Provigil slated to lose patent protection in 2012, specialty pharma also is looking beyond Nuvigil for answers.